Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:47:32.273Z.
Calculation as of: 2026-10-06T14:47:32.273Z.
Quote observation: 2026-10-06T14:44:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2df09dd0ed9c1c1ce3105b02e8ae50a0cdbf9b2118b3d67a1d250f1ffe9c40c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-05-14.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
EBITDA YIELD AVG TTM
N/A
EBITDA YIELD AVG 3Y
N/A
EBITDA YIELD AVG 5Y
N/A
EBITDA YIELD AVG 10Y
N/A
EBITDA YIELD AVG 15Y
N/A
EBITDA YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$218.14M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.64M
EBITDA Yield
6.95%
TTM Avg
4.54%
3Y Avg
3.13%
5Y Avg
3.13%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $223.58M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $225.85M | N/A | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $221.42M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $218.14M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $229.14M | N/A | 0.97% | 0.50% | 0.50% |
| BioAge Labs Inc. (BIOA)vs › | $232.73M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 6.95% | 4.54% | 3.13% | 3.13% |
| Compugen Ltd. (CGEN)vs › | $213.22M | N/A | 17.11% | 12.89% | 12.89% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $211.96M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.77M | N/A | 6.75% | 3.64% | 3.64% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA YIELD |
|---|---|
| 2026-05-14 | 243.39% |
| 2026-05-13 | 124.29% |
| 2026-05-12 | 149.09% |
| 2026-05-11 | 123.08% |
| 2026-05-08 | 119.60% |
| 2026-05-07 | 149.97% |
| 2026-05-06 | 138.52% |
| 2026-05-05 | 139.28% |
| 2026-05-04 | 144.02% |
| 2026-05-01 | 164.55% |
| 2026-04-30 | 216.43% |
| 2026-04-29 | 220.18% |
| 2026-04-28 | 178.42% |
| 2026-04-27 | 238.82% |
| 2026-04-24 | 162.44% |
| 2026-04-23 | 157.41% |
| 2026-04-22 | 170.06% |
| 2026-04-21 | 186.27% |
| 2026-04-20 | 148.22% |
| 2026-04-17 | 147.36% |
| 2026-04-16 | 143.21% |
| 2026-04-15 | 144.02% |
| 2026-04-14 | 158.39% |
| 2026-04-13 | 211.03% |
| 2026-04-10 | 201.01% |
| 2026-04-09 | 99.85% |
| 2026-04-08 | 97.55% |
| 2026-04-07 | 110.74% |
| 2026-04-06 | 132.04% |
| 2026-04-02 | 123.68% |
| 2026-04-01 | 145.67% |
| 2026-03-31 | 232.26% |
| 2026-03-30 | 346.26% |
| 2026-03-27 | 382.79% |
| 2026-03-26 | 224.07% |
| 2026-03-25 | 182.26% |
| 2026-03-24 | 243.39% |
| 2026-03-23 | 196.35% |
| 2026-03-20 | 250.60% |
| 2026-03-19 | 216.43% |
| 2026-03-18 | 253.10% |
| 2026-03-17 | 182.26% |
| 2026-03-16 | 234.41% |
| 2026-03-13 | 236.59% |
| 2026-03-12 | 243.39% |
| 2026-03-11 | 191.90% |
| 2026-03-10 | 155.48% |
| 2026-03-09 | 180.96% |
| 2026-03-06 | 187.65% |
| 2026-03-05 | 144.02% |
| 2026-02-11 | 278.30% |
| 2026-02-10 | 218.07% |
| 2026-02-09 | 124.78% |
| 2026-02-06 | 119.40% |
| 2026-02-05 | 185.26% |
| 2026-02-04 | 78.70% |
| 2026-02-03 | 60.62% |
| 2026-02-02 | 63.04% |
| 2026-01-30 | 87.39% |
| 2026-01-29 | 82.21% |
| 2026-01-28 | 93.28% |
| 2026-01-27 | 66.84% |
| 2026-01-26 | 52.08% |
| 2026-01-23 | 43.33% |
| 2026-01-22 | 39.33% |
| 2026-01-21 | 46.60% |
| 2026-01-20 | 61.98% |
| 2026-01-16 | 49.97% |
| 2026-01-15 | 42.33% |
| 2026-01-14 | 38.38% |
| 2026-01-13 | 38.78% |
| 2026-01-12 | 49.52% |
| 2026-01-09 | 43.33% |
| 2026-01-08 | 57.18% |
| 2026-01-07 | 57.78% |
| 2026-01-06 | 96.53% |
| 2026-01-05 | 86.71% |
| 2026-01-02 | 58.39% |
| 2025-12-31 | 29.81% |
| 2025-12-30 | 30.55% |
| 2025-12-29 | 27.79% |
| 2025-12-26 | 25.26% |
| 2025-12-24 | 23.49% |
| 2025-12-23 | 23.39% |
| 2025-12-22 | 23.59% |
| 2025-12-19 | 30.63% |
| 2025-12-18 | 31.77% |
| 2025-12-17 | 26.46% |
| 2025-12-16 | 22.67% |
| 2025-12-15 | 24.16% |
| 2025-12-12 | 22.77% |
| 2025-12-11 | 21.96% |
| 2025-12-10 | 21.32% |
| 2025-12-09 | 22.67% |
| 2025-12-08 | 23.69% |
| 2025-12-05 | 21.96% |
| 2025-12-04 | 30.55% |
| 2025-12-03 | 76.01% |
| 2025-12-02 | 588.71% |
| 2025-12-01 | 205.91% |
| 2025-11-28 | 132.22% |
| 2025-11-26 | 129.14% |
| 2025-11-25 | 163.41% |
| 2025-11-24 | 300.97% |
| 2025-11-21 | 148.12% |
| 2025-11-20 | 621.74% |
| 2025-11-19 | 507.80% |
| 2025-11-18 | 122.03% |
| 2025-11-17 | 152.19% |
| 2025-11-14 | 179.27% |
| 2025-11-13 | 168.38% |
| 2025-11-12 | 133.82% |
| 2025-11-11 | 429.15% |
| 2025-11-10 | 278.30% |
